Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

NVS

Novartis (NVS)

Novartis AG
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:NVS
DateTimeSourceHeadlineSymbolCompany
16/09/202422:44Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:NVSNovartis AG
16/09/202422:12Edgar (US Regulatory)Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNYSE:NVSNovartis AG
16/09/202420:03IH Market NewsIntel Secures $3.5 Billion Subsidy, Stellantis Backs EU Emissions Targets, BP and Apollo Reach $1 Billion DealNYSE:NVSNovartis AG
11/09/202408:53AllPennyStocks.comJunior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving LivesNYSE:NVSNovartis AG
05/09/202422:00GlobeNewswire Inc.Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14NYSE:NVSNovartis AG
29/08/202402:16Business WireLindy Biosciences stringe un accordo di licenza e collaborazione con Novartis per la somministrazione innovativa di farmaci multitargetNYSE:NVSNovartis AG
29/08/202402:07Business WireLindy Biosciences conclut un accord de licence et de collaboration avec Novartis pour l’innovation en matière d’administration de médicaments à cibles multiplesNYSE:NVSNovartis AG
29/08/202402:06Business WireLindy Biosciences schließt Lizenzierungs- und Kooperationsvereinbarung mit Novartis für Wirkstoffabgabeinnovation für mehrere Zielmoleküle abNYSE:NVSNovartis AG
28/08/202420:58Business WireLindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery InnovationNYSE:NVSNovartis AG
26/08/202422:58IH Market NewsIBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without AstronautsNYSE:NVSNovartis AG
16/08/202406:30Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NYSE:NVSNovartis AG
14/08/202406:31Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NYSE:NVSNovartis AG
13/08/202405:30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:NVSNovartis AG
08/08/202409:38PR Newswire (US)Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)NYSE:NVSNovartis AG
06/08/202419:44IH Market NewsGoogle Faces Antitrust Ruling; SunPower Files for Bankruptcy and Business Sale – Latest Business NewsNYSE:NVSNovartis AG
03/08/202406:30Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NYSE:NVSNovartis AG
02/08/202406:30Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NYSE:NVSNovartis AG
01/08/202406:30Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NYSE:NVSNovartis AG
31/07/202406:30Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NYSE:NVSNovartis AG
30/07/202421:00GlobeNewswire Inc.Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNYSE:NVSNovartis AG
30/07/202406:30Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NYSE:NVSNovartis AG
26/07/202406:30Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NYSE:NVSNovartis AG
19/07/202406:30Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NYSE:NVSNovartis AG
18/07/202420:09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:NVSNovartis AG
18/07/202419:53IH Market NewsTSMC Net Profit Hits $7.6B; Nokia Sees 32% Decline in Operating Profit; Novartis Boosts Outlook After Profit SurgeNYSE:NVSNovartis AG
12/07/202406:30Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NYSE:NVSNovartis AG
18/06/202406:30Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NYSE:NVSNovartis AG
25/05/202420:15PR Newswire (US)Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolioNYSE:NVSNovartis AG
25/05/202420:00PR Newswire (US)Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placeboNYSE:NVSNovartis AG
25/05/202406:31Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NYSE:NVSNovartis AG
 Showing the most relevant articles for your search:NYSE:NVS